Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 8/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698754 | 1.00 | HPGD (0.41) | HPGDALDH1A1ALOX5MGLLRAB9A | |
| Hydrochloric Acid SCHEMBL5642910 | 0.99 | ALDH1A1 (0.43) | HPGDALDH1A1ALOX5MGLLRAB9A | |
| Hydrochloric Acid SCHEMBL5640637 | 0.99 | ALDH1A1 (0.43) | HPGDALDH1A1ALOX5MGLLRAB9A | |
| SCHEMBL4699359 | 0.97 | ALDH1A1 (0.37) | HPGDALDH1A1ALOX5MGLLRAB9A | |
| Hydrochloric Acid SCHEMBL5642464 | 0.96 | ALDH1A1 (0.39) | HPGDALDH1A1ALOX5MGLLRAB9A | |
| SCHEMBL4699894 | 0.91 | HPGD (0.40) | HPGDALDH1A1RAB9ANPC1KMT2A | |
| SCHEMBL4700238 | 0.91 | ALDH1A1 (0.40) | HPGDALDH1A1ALOX5MGLLRAB9A | |
| Hydrochloric Acid SCHEMBL5643097 | 0.90 | ALDH1A1 (0.41) | HPGDALDH1A1ALOX5MGLLRAB9A | |
| SCHEMBL4701758 | 0.85 | RAB9A (0.39) | HPGDALDH1A1ALOX5RAB9ANPC1 | |
| SCHEMBL4700290 | 0.84 | NPC1 (0.42) | HPGDALDH1A1RAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527068-B1 | NOVEL ARYLIMIDAZOLE DERIVATIVES, THEIR USE AS NO-SYNTASE INHIBITORS AND AS MODULATORS OF SODIUM CHANNELS | SOD CONSEILS RECH APPLIC (FR) | 2008-01-09 | — | — | EP | claimed |
| US-7192975-B2 | Arylimidazole derivatives, preparation and therapeutic used thereof | SOCIETE DE CONSEILS DE RECHERCHES ET D''APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-20 | — | — | US | claimed |
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | IPSEN PHARMA S.A.S. (FR) | 2005-10-20 | — | — | US | claimed |
| EP-1527068-A2 | NOVEL ARYLIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-05-04 | — | — | EP | claimed |
| WO-2004011402-A2 | NOVEL ARYLIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-02-05 | — | — | WO | claimed |
| EP-1527068-B1 | NOVEL ARYLIMIDAZOLE DERIVATIVES, THEIR USE AS NO-SYNTASE INHIBITORS AND AS MODULATORS OF SODIUM CHANNELS | SOD CONSEILS RECH APPLIC (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-7192975-B2 | Arylimidazole derivatives, preparation and therapeutic used thereof | SOCIETE DE CONSEILS DE RECHERCHES ET D''APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-20 | — | — | US | disclosed |
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | IPSEN PHARMA S.A.S. (FR) | 2005-10-20 | — | — | US | disclosed |
| EP-1527068-A2 | NOVEL ARYLIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011402-A2 | NOVEL ARYLIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | OPRL1, CBR3, SCN5A | HPGD 1188/4885ALDH1A1 2100/4885ALOX5 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.